Source comparison
CJC/Ipamorelin Blend vs Other Growth Hormone Secretagogues: Research Comparison
The following table compares the CJC/Ipamorelin Blend to commonly studied single-peptide and oral growth hormone secretagogues across key research parameters: | Compound | Mechanism | Half-Life | GH Pulse Pattern | Cortisol/Prolactin Effect | Typical Research
This comparison does not assign a generated winner or score.
- The following table compares the CJC/Ipamorelin Blend to commonly studied single-peptide and oral growth hormone secretagogues across key research parameters:
- | Compound | Mechanism | Half-Life | GH Pulse Pattern | Cortisol/Prolactin Effect | Typical Research Dose | Professional Assessment ||—|—|—|—|—|—|| CJC/Ipamorelin Blend | Dual GHRH + ghrelin agonist | 6–8 days (CJC) / 2 hours (Ipa) | Sustained pulsatile | Minimal elevation | 100–200mcg each, daily | Gold standard for research requiring physiological GH pulsatility with extended duration || CJC-1295 (solo) | GHRH analog with DAC | 6–8 days | Sustained baseline, blunted pulses | No significant effect | 100–200mcg, 1–2×/week | Effective for baseline GH elevation but lacks pulse amplification. Inferior to blend for most applications || Ipamorelin (solo) | Selective ghrelin agonist | 2 hours | Discrete pulses, no baseline extension | No significant effect | 200–300mcg, 2–3×/day | Excellent selectivity but requires frequent dosing. Pulse duration shorter than blend || MK-677 (Ibutamoren) | Oral ghrelin mimetic | 24 hours | Sustained elevation, no pulsatility | Moderate cortisol increase, sig
- Research models requiring isolated GH effects without cortisol confounding consistently favor the CJC/Ipamorelin Blend over older GHRP analogs. The blend's ability to maintain pulsatile secretion while extending pulse duration makes it uniquely suited for studies examining GH's role in recovery, tissue repair, and metabolic regulation where preserving normal feedback loops is essential.